Figure 5.

WES of sorted myeloid, T, and NK cells. (A) Evaluation by flow cytometry of the purity of sorted NK, T, and myeloid cells from 1 representative case (patient 105). (B) Purity evaluation of fluorescence activated cell sorting–delineated cells for all samples. *For 2 patients, the number of sorted myeloid cells was too low (<100 000) to perform purity control analysis. (C) WES results for 4 TET2-mutated patients. Venn diagrams represents the number of mutations in NK cells and myeloid cells as compared with the reference sample (T cell). Patient 105 analysis also includes a tumoral sample (AITL) collected 2 years before the occurrence of the CLPD-NK. Mentioned mutations correspond to pathogenic variants and/or variants related in OncoKB database.